Christopher R Cogle, M.D.
Professor
Department:
MD-HEMATOLOGY/ONCOLOGY
Business Phone:
(352) 273-7832
Business Email:
christopher.cogle@medicine.ufl.edu
About Christopher R Cogle
Dr. Christopher R. Cogle is Chief Medical Officer for Florida Medicaid, Professor at the University of Florida, and Founding Director of the Florida Health Policy Leadership Academy at the Bob Graham Center for Public Service. His work spans pioneering discoveries in blood stem cells to first-in-human clinical trials, alongside shaping innovative health policies. Dr. Cogle’s recognitions by the Harvard Business School, American Cancer Society, Leukemia & Lymphoma Society, Milbank Memorial Fund, and the National Academy of Medicine Emerging Leaders in Health and Medicine Fellowship highlight his impact in bridging the gap between research and societal change.
Related Links:
Accomplishments
National Achievement Award
2024
·
American Cancer Society
Fellow
2023
·
Milbank Memorial Fund
Presidential Honorable Mention
2023
·
Florida Public Health Association
Emerging Leader in Health and Medicine Scholar
2020
·
National Academy of Medicine
Clinical Trials Award
2018
·
UF Health Cancer Center
Research Prize
2016
·
UF Department of Medicine
Research Prize
2016
·
Harvard Business School Precision Trials Challenge
Research Prize
2014
·
UF Department of Medicine
Customer Service Key Award for Excellent Patient Care
2013
·
UF Health Shands Hospital
Bench to Bedside Award
2012
·
University of Florida
Research Award
2012
·
UF Department of Medicine
Scholar in Clinical Research
2012
·
Leukemia and Lymphoma Society
Best in Research
2011
·
University of Florida
Center of Excellence in Myelodysplastic Syndromes
2009
·
MDS Foundation
Excellence in Teaching Award
2008
·
University of Florida
Best in Research
2006
·
University of Florida
Top 10 US Young Stem Cell Scientist
2005
·
British Council
First Prize in Research
2004
·
Joint Cancer Conference of the Florida Universities
Young Investor Award
2003
·
American Society of Clinical Oncology
NIH Loan Repayment Award
2002
·
NIH
Alpha Omega Alpha
1998
·
Alpha Omega Alpha
Vigil Honor
1989
·
Order of the Arrow
Eagle Scout
1987
·
Boy Scouts of America
Teaching Profile
Courses Taught
2018-2021
IDH2930 (Un)common read
2020
GMS6001 Fundamentals of Biomedical Sciences I
2019-2020,2022
GMS6847 Translational Research and Therapeutics: Bench, Bedside, Community, & Policy
2020-2021
BMS6631 Hematology
2019
PHA6136 Clinical Applications of Precision Medicine: Oncology
2019
GMS5905 Special Topics in Biomedical Sciences
2018
MDT7090 Elective Topics
2018
GMS7980 Research for Doctoral Dissertation
2018
BME7980 Research for Doctoral Dissertation
2017
BMS4905 Medical Sciences Senior Research
2008,2011-2017
GMS6335 Advanced Stem Cell Biology: Tissue Engineering
2021
PHA6935 Selected Topics in Pharmacy
Board Certifications
-
OncologyAmerican Board of Internal Medicine
Clinical Profile
Dr. Cogle’s clinical expertise is in blood cancers and blood & marrow transplant. He is known for his expertise in the myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and myelofibrosis (MF). Dr. Cogle is a clinician-scientist who creates and leads clinical trials for patients with cancer. He has earned distinctions of excellence by the MDS International Foundation, the Leukemia & Lymphoma Society, the American Cancer Society.
Specialties
- Cancer
Areas of Interest
- Acute myeloid leukemia (AML) – children
- Acute myeloid leukemia – adult
- Aplastic anemia
- Bone Marrow Aspiration
- Bone Marrow Biopsy
- Bone marrow culture
- Bone marrow transplant
- Cancer treatment information
- Cord blood transplantation
- Diet – cancer treatment
- Diet and Cancer
- Genetics
- Myelodysplastic Syndromes (MDS)
- Myelodysplastic syndrome
- Secondary aplastic anemia
- Stem cell research
Research Profile
Christopher R. Cogle, M.D. is a physician and scientist with research focus on cancer and health policy. In his early career Dr. Cogle discovered that blood stem cells make blood vessels and used that biology to invent new therapeutics and diagnostics for people with cancer and heart disease. In his mid career, as a Leukemia & Lymphoma Society Scholar in Clinical Research, he translated laboratory research discoveries into investigator-initiated clinical trials. Dr. Cogle has also made major discoveries in cancer epidemiology and was elected to lead Florida’s cancer prevention and control efforts at the state level, producing the Florida Cancer Plan, leading statewide campaigns for improved cancer prevention and control, and advising the Florida Legislature, Florida Secretary of Health, and Florida Governor on evidence-based strategies to reduce the state’s cancer burden. In 2020, Dr. Cogle was selected by the National Academy of Medicine as an Emerging Leader in Health and Medicine Scholar. In 2021, Dr.Cogle founded the Florida Health Policy Leadership Academy at the Bob Graham Center for Public Service. His academy team of faculty trains Florida’s community leaders in promoting health and preventing disease and disease progression for Florida’s 21 million residents and 100 million visitors. In 2023, he was selected by the Milbank Memorial Foundation as a state health policy fellow.
Open Researcher and Contributor ID (ORCID)
0000-0001-5422-6863
Areas of Interest
- Allogeneic Hematopoietic Cell Transplantation
- Bone marrow transplantation
- Cancer
- Cancer Genetics
- Cancer Informatics
- Cancer Screening
- Cancer prevention
- Digital Health
- Genetics
- Haplo-identical Stem Cell Transplantation
- Health Outcomes
- Health Policy
- Health outcomes research
- Healthcare policies
- Leukemia
- Population Health
- Targeted Cancer Therapy
- Telehealth
- health services research
Publications
Academic Articles
2025
Medicaid and the Promise for Cure.
JAMA pediatrics.
179(2):197-202
[DOI] 10.1001/jamapediatrics.2024.5100.
[PMID] 39804636.
2024
Integrating firearm storage and safety devices into health care
Health Affairs Scholar.
2(9)
[DOI] 10.1093/haschl/qxae105.
[PMID] 39253561.
2024
Long-read epigenomic diagnosis and prognosis of Acute Myeloid Leukemia.
Research square.
[DOI] 10.21203/rs.3.rs-5450972/v1.
[PMID] 39711573.
2024
Participation in Tobacco Cessation Programs Among Medicaid Managed Care Enrollees in Florida
Healthcare.
12(22)
[DOI] 10.3390/healthcare12222319.
[PMID] 39595516.
2024
Prevalence of Underreported Nicotine Exposure Among US Nonsmoking Adults: A Comparison of Self-Reported Exposure and Serum Cotinine Levels From NHANES 2013–2020
Nicotine and Tobacco Research.
26(3):298-306
[DOI] 10.1093/ntr/ntad165.
2023
Access to Prenatal Care Among Patients With Opioid Use Disorder in Florida: Findings From a Secret Shopper Study.
Obstetrics and gynecology.
142(5):1162-1168
[DOI] 10.1097/AOG.0000000000005315.
[PMID] 37856854.
2023
Comparative effectiveness of mobile health smoking cessation approaches among underserved patients in primary care: Study protocol for the PROMOTE-UP trial.
Contemporary clinical trials.
127
[DOI] 10.1016/j.cct.2023.107120.
[PMID] 36804046.
2023
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial.
Cancer.
129(15):2308-2320
[DOI] 10.1002/cncr.34780.
[PMID] 37078412.
2023
Genome-wide CRISPR/Cas9 screen identifies etoposide response modulators associated with clinical outcomes in pediatric AML
Blood Advances.
7(9):1769-1783
[DOI] 10.1182/bloodadvances.2022007934.
[PMID] 36111891.
2023
Home Modifications for Older Adults: A Systematic Review.
Journal of applied gerontology : the official journal of the Southern Gerontological Society.
42(5):1151-1164
[DOI] 10.1177/07334648231151669.
[PMID] 36655622.
2023
Targeting Redundant ROBO1 and SDF-1 Pathways Prevents Adult Hemangioblast Derived-EPC and CEC Activity Effectively Blocking Tumor Neovascularization.
Stem cell reviews and reports.
19(4):928-941
[DOI] 10.1007/s12015-022-10498-7.
[PMID] 36652143.
2023
Transplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care.
Transplantation and cellular therapy.
29(7):460.e1-460.e9
[DOI] 10.1016/j.jtct.2023.04.011.
[PMID] 37086851.
2022
DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks.
Clinical cancer research : an official journal of the American Association for Cancer Research.
28(4):756-769
[DOI] 10.1158/1078-0432.CCR-21-2863.
[PMID] 34716195.
2022
HOTTIP-dependent R-loop formation regulates CTCF boundary activity and TAD integrity in leukemia.
Molecular cell.
82(4):833-851.e11
[DOI] 10.1016/j.molcel.2022.01.014.
[PMID] 35180428.
2022
Impact of the COVID-19 Pandemic on Colorectal and Prostate Cancer Screening in a Large U.S. Health System
Healthcare.
10(2)
[DOI] 10.3390/healthcare10020264.
[PMID] 35206878.
2022
Integrative analysis of drug response and clinical outcome in acute myeloid leukemia.
Cancer cell.
40(8):850-864.e9
[DOI] 10.1016/j.ccell.2022.07.002.
[PMID] 35868306.
2022
Medicaid’s Moment for Protecting and Promoting Women’s Health.
JAMA.
328(21):2105-2106
[DOI] 10.1001/jama.2022.21048.
[PMID] 36374488.
2022
Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
40(7):772-783
[DOI] 10.1200/JCO.21.01422.
[PMID] 34990262.
2022
Specialized Proresolving Mediators in Symptomatic Women With Coronary Microvascular Dysfunction (from the Women’s Ischemia Trial to Reduce Events in Nonobstructive CAD [WARRIOR] Trial).
The American journal of cardiology.
162:1-5
[DOI] 10.1016/j.amjcard.2021.09.015.
[PMID] 34728061.
2021
A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Cancers.
13(16)
[DOI] 10.3390/cancers13164113.
[PMID] 34439266.
2021
Building a precision oncology workforce by multidisciplinary and case-based learning
BMC Medical Education.
21(1)
[DOI] 10.1186/s12909-021-02500-6.
[PMID] 33499867.
2021
Finding incident cancer cases through outpatient oncology clinic claims data and integration into a state cancer registry
Cancer Causes & Control.
32(2):199-202
[DOI] 10.1007/s10552-020-01368-z.
2021
Following the Breadcrumbs of Palliative Care Financial Sustainability to Big Data.
Journal of palliative medicine.
24(5):649-650
[DOI] 10.1089/jpm.2021.0018.
[PMID] 33945316.
2021
Implementation of Cancer Plans in the United States: A Review
Healthcare.
9(3)
[DOI] 10.3390/healthcare9030291.
[PMID] 33800077.
2021
Novel CD33 antibodies unravel localization, biology and therapeutic implications of CD33 isoforms.
Future oncology (London, England).
17(3):263-277
[DOI] 10.2217/fon-2020-0746.
[PMID] 33356566.
2021
Post-hoc Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMA.
Frontiers in oncology.
11
[DOI] 10.3389/fonc.2021.806243.
[PMID] 35096610.
2021
Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes.
International journal of laboratory hematology.
43(3):426-432
[DOI] 10.1111/ijlh.13400.
[PMID] 33220019.
2021
Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436
Cancers.
13(21)
[DOI] 10.3390/cancers13215287.
[PMID] 34771451.
2021
Vaccine Enthusiasm and Hesitancy in Cancer Patients and the Impact of a Webinar
Healthcare.
9(3)
[DOI] 10.3390/healthcare9030351.
[PMID] 33808758.
2020
Cancer in the Time of Coronavirus: A Call for Crisis Oncology Standards of Care
Healthcare.
8(3)
[DOI] 10.3390/healthcare8030214.
[PMID] 32708922.
2020
Clinical Application of Computational Methods in Precision Oncology: A Review.
JAMA oncology.
6(8):1282-1286
[DOI] 10.1001/jamaoncol.2020.1247.
[PMID] 32407443.
2020
Clinical predictors of delayed engraftment in autologous hematopoietic cell transplant recipients.
Hematology/oncology and stem cell therapy.
13(1):23-31
[DOI] 10.1016/j.hemonc.2019.08.003.
[PMID] 31629722.
2020
Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect® MDS/AML Disease Registry.
EJHaem.
1(1):58-68
[DOI] 10.1002/jha2.16.
[PMID] 35847712.
2020
Functional Dependency Analysis Identifies Potential Druggable Targets in Acute Myeloid Leukemia
Cancers.
12(12)
[DOI] 10.3390/cancers12123710.
[PMID] 33321907.
2020
Identification of Lenalidomide Sensitivity and Resistance Mechanisms in Non-Del(5q) Myelodysplastic Syndromes
International Journal of Molecular Sciences.
21(9)
[DOI] 10.3390/ijms21093323.
[PMID] 32397113.
2020
Identification of Unique mRNA and miRNA Expression Patterns in Bone Marrow Hematopoietic Stem and Progenitor Cells After Trauma in Older Adults.
Frontiers in immunology.
11
[DOI] 10.3389/fimmu.2020.01289.
[PMID] 32670283.
2020
Patient and physician perceptions about blood transfusions in the myelodysplastic syndromes
Leukemia Research.
96
[DOI] 10.1016/j.leukres.2020.106425.
2020
RNA Demethylase ALKBH5 Selectively Promotes Tumorigenesis and Cancer Stem Cell Self-Renewal in Acute Myeloid Leukemia.
Cell stem cell.
27(1):64-80.e9
[DOI] 10.1016/j.stem.2020.04.009.
[PMID] 32402250.
2020
Safety, feasibility and preliminary efficacy of single agent combretastatin A1 diphosphate (OXi4503) in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes.
British journal of haematology.
189(5):e211-e213
[DOI] 10.1111/bjh.16629.
[PMID] 32236943.
2019
A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients
Blood Advances.
3(12):1837-1847
[DOI] 10.1182/bloodadvances.2018028316.
[PMID] 31208955.
2019
A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia
Cancers.
12(1)
[DOI] 10.3390/cancers12010074.
[PMID] 31888052.
2019
Computational modeling of early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) to identify personalized therapy using genomics
Leukemia Research.
78:3-11
[DOI] 10.1016/j.leukres.2019.01.003.
2019
Continuous Rural-Urban Coding for Cancer Disparity Studies: Is It Appropriate for Statistical Analysis?
International Journal of Environmental Research and Public Health.
16(6)
[DOI] 10.3390/ijerph16061076.
[PMID] 30917515.
2019
HOTTIP lncRNA Promotes Hematopoietic Stem Cell Self-Renewal Leading to AML-like Disease in Mice.
Cancer cell.
36(6):645-659.e8
[DOI] 10.1016/j.ccell.2019.10.011.
[PMID] 31786140.
2019
Improving Cancer Diagnosis and Care: Patient Access to Oncologic Imaging Expertise.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
37(20):1690-1694
[DOI] 10.1200/JCO.18.01970.
[PMID] 31050908.
2019
Interleukin-8 blockade prevents activated endothelial cell mediated proliferation and chemoresistance of acute myeloid leukemia
Leukemia Research.
84
[DOI] 10.1016/j.leukres.2019.106180.
[PMID] 31299413.
2019
Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del(5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical Trial.
Clinical lymphoma, myeloma & leukemia.
19(4):251-254
[DOI] 10.1016/j.clml.2018.12.014.
2019
Predicting response to BET inhibitors using computational modeling: A BEAT AML project study.
Leukemia research.
77:42-50
[DOI] 10.1016/j.leukres.2018.11.010.
[PMID] 30642575.
2019
Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis.
Leukemia research.
81:43-49
[DOI] 10.1016/j.leukres.2019.04.005.
[PMID] 31009835.
2018
CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopenia
Leukemia Research.
72:79-85
[DOI] 10.1016/j.leukres.2018.08.001.
2018
CD34+ chimerism analysis for minimal residual disease monitoring after allogeneic hematopoietic cell transplantation.
Leukemia research.
74:110-112
[DOI] 10.1016/j.leukres.2018.10.007.
[PMID] 30401521.
2018
CTCF boundary remodels chromatin domain and drives aberrant HOX gene transcription in acute myeloid leukemia.
Blood.
132(8):837-848
[DOI] 10.1182/blood-2017-11-814319.
[PMID] 29760161.
2018
Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study.
Leukemia research.
64:34-41
[DOI] 10.1016/j.leukres.2017.11.008.
[PMID] 29175379.
2018
Exploring the Structure-Activity Relationship and Mechanism of a Chromene Scaffold (CXL Series) for Its Selective Antiproliferative Activity toward Multidrug-Resistant Cancer Cells.
Journal of medicinal chemistry.
61(15):6892-6903
[DOI] 10.1021/acs.jmedchem.8b00813.
[PMID] 29995404.
2018
Functional genomic landscape of acute myeloid leukaemia.
Nature.
562(7728):526-531
[DOI] 10.1038/s41586-018-0623-z.
[PMID] 30333627.
2018
Infusion of Alloanergized Donor Lymphocytes after CD34-selected Haploidentical Myeloablative Hematopoietic Stem Cell Transplantation.
Clinical cancer research : an official journal of the American Association for Cancer Research.
24(17):4098-4109
[DOI] 10.1158/1078-0432.CCR-18-0449.
[PMID] 29769208.
2018
Poor peripheral blood stem cell mobilization affects long-term outcomes in multiple myeloma patients undergoing autologous stem cell transplantation.
Journal of clinical apheresis.
33(1):29-37
[DOI] 10.1002/jca.21556.
[PMID] 28556233.
2018
Using Social Media to Assess Care Coordination Goals and Plans for Leukemia Patients and Survivors
Translational Behavioral Medicine.
8(3, SI):481-491
[DOI] 10.1093/tbm/ibx075.
2017
Association of breast carcinoma growth with a non-canonical axis of IFNγ/IDO1/TSP1.
Oncotarget.
8(49):85024-85039
[DOI] 10.18632/oncotarget.18781.
[PMID] 29156701.
2017
Computational drug treatment simulations on projections of dysregulated protein networks derived from the myelodysplastic mutanome match clinical response in patients.
Leukemia research.
52:1-7
[DOI] 10.1016/j.leukres.2016.11.004.
[PMID] 27855285.
2017
Computational Modeling and Treatment Identification in the Myelodysplastic Syndromes.
Current hematologic malignancy reports.
12(5):478-483
[DOI] 10.1007/s11899-017-0412-z.
[PMID] 28913766.
2017
Early treatment initiation in lower-risk myelodysplastic syndromes produces an earlier and higher rate of transfusion independence.
Leukemia research.
60:123-128
[DOI] 10.1016/j.leukres.2017.07.008.
[PMID] 28818807.
2017
Ex Vivo Oncolytic Virotherapy with Myxoma Virus Arms Multiple Allogeneic Bone Marrow Transplant Leukocytes to Enhance Graft versus Tumor.
Molecular therapy oncolytics.
4:31-40
[DOI] 10.1016/j.omto.2016.12.002.
[PMID] 28345022.
2017
Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemia.
Blood cancer journal.
7(12)
[DOI] 10.1038/s41408-017-0007-x.
[PMID] 29176662.
2017
Peripheral Blood Cytokine Levels After Acute Myocardial Infarction: IL-1β- and IL-6-Related Impairment of Bone Marrow Function.
Circulation research.
120(12):1947-1957
[DOI] 10.1161/CIRCRESAHA.116.309947.
[PMID] 28490433.
2017
Refractory macrocytic anemias in patients with clonal hematopoietic disorders and isolated mutations of the spliceosome gene ZRSR2.
Leukemia research.
61:104-107
[DOI] 10.1016/j.leukres.2017.09.002.
[PMID] 28942350.
2017
The Incidence and Health Care Resource Burden of the Myelodysplastic Syndromes in Patients in Whom First-Line Hypomethylating Agents Fail.
The oncologist.
22(4):379-385
[DOI] 10.1634/theoncologist.2016-0211.
[PMID] 28283585.
2017
The role and clinical implications of the endosteal niche and osteoblasts in regulating leukemia.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.
19(9):1059-1066
[DOI] 10.1007/s12094-017-1642-1.
[PMID] 28281084.
2016
A new model to predict remission status in AML patients based on day 14 bone marrow biopsy.
Leukemia research.
46:69-73
[DOI] 10.1016/j.leukres.2016.04.013.
[PMID] 27132034.
2016
Acute myeloid leukemia in the vascular niche
Cancer Letters.
380(2):552-560
[DOI] 10.1016/j.canlet.2015.05.007.
2016
An injectable capillary-like microstructured alginate hydrogel improves left ventricular function after myocardial infarction in rats.
International journal of cardiology.
220:149-54
[DOI] 10.1016/j.ijcard.2016.06.158.
[PMID] 27379917.
2016
Angiotensin II Regulation of Proliferation, Differentiation, and Engraftment of Hematopoietic Stem Cells.
Hypertension (Dallas, Tex. : 1979).
67(3):574-84
[DOI] 10.1161/HYPERTENSIONAHA.115.06474.
[PMID] 26781279.
2016
Bone marrow cell characteristics associated with patient profile and cardiac performance outcomes in the LateTIME-Cardiovascular Cell Therapy Research Network (CCTRN) trial.
American heart journal.
179:142-50
[DOI] 10.1016/j.ahj.2016.06.018.
[PMID] 27595689.
2016
Chemosensitizing AML cells by targeting bone marrow endothelial cells.
Experimental hematology.
44(5):363-377.e5
[DOI] 10.1016/j.exphem.2016.02.003.
[PMID] 26898708.
2016
Circulating progenitor cells and coronary microvascular dysfunction: Results from the NHLBI-sponsored Women’s Ischemia Syndrome Evaluation – Coronary Vascular Dysfunction Study (WISE-CVD).
Atherosclerosis.
253:111-117
[DOI] 10.1016/j.atherosclerosis.2016.08.026.
[PMID] 27596135.
2016
Clinical significance of in vivo cytarabine-induced gene expression signature in AML.
Leukemia & lymphoma.
57(4):909-20
[DOI] 10.3109/10428194.2015.1086918.
[PMID] 26366682.
2016
Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
BMC cancer.
16
[DOI] 10.1186/s12885-016-2710-6.
[PMID] 27538433.
2016
Cost-effectiveness of treatments for high-risk myelodysplastic syndromes after failure of first-line hypomethylating agent therapy.
Expert review of pharmacoeconomics & outcomes research.
16(2):275-84
[DOI] 10.1586/14737167.2016.1096200.
[PMID] 26589773.
2016
Effect of melphalan 140 mg/m(2) vs 200 mg/m(2) on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantation-a single center experience.
Clinical transplantation.
30(8):894-900
[DOI] 10.1111/ctr.12762.
[PMID] 27219740.
2016
Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes.
Leukemia.
30(4):889-96
[DOI] 10.1038/leu.2015.265.
[PMID] 26442612.
2016
Ex vivo virotherapy with myxoma virus does not impair hematopoietic stem and progenitor cells.
Cytotherapy.
18(3):465-80
[DOI] 10.1016/j.jcyt.2015.12.007.
[PMID] 26857235.
2016
Identification of Bone Marrow Cell Subpopulations Associated With Improved Functional Outcomes in Patients With Chronic Left Ventricular Dysfunction: An Embedded Cohort Evaluation of the FOCUS-CCTRN Trial.
Cell transplantation.
25(9):1675-1687
[PMID] 26590374.
2016
Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic Strategies
Viruses.
8(3)
[DOI] 10.3390/v8030085.
[PMID] 27011200.
2015
Bone marrow characteristics associated with changes in infarct size after STEMI: a biorepository evaluation from the CCTRN TIME trial.
Circulation research.
116(1):99-107
[DOI] 10.1161/CIRCRESAHA.116.304710.
[PMID] 25406300.
2015
Bone marrow niche in the myelodysplastic syndromes.
Leukemia research.
39(10):1020-7
[DOI] 10.1016/j.leukres.2015.06.017.
[PMID] 26276090.
2015
Endothelial cell derived angiocrine support of acute myeloid leukemia targeted by receptor tyrosine kinase inhibition
Leukemia Research.
39(9):984-989
[DOI] 10.1016/j.leukres.2015.05.015.
[PMID] 26189107.
2015
Incidence and Burden of the Myelodysplastic Syndromes.
Current hematologic malignancy reports.
10(3):272-81
[DOI] 10.1007/s11899-015-0269-y.
[PMID] 26134527.
2015
Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia.
The oncologist.
20(12):1404-12
[DOI] 10.1634/theoncologist.2015-0165.
[PMID] 26463870.
2015
Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies.
PloS one.
10(8)
[DOI] 10.1371/journal.pone.0135520.
[PMID] 26296092.
2015
Poor Peripheral Blood Stem Cell Mobilization Correlates With Worse Long-Term Outcomes in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Biology of Blood and Marrow Transplantation.
21(2, 1)
[DOI] 10.1016/j.bbmt.2014.11.175.
2015
Prevention of EBV lymphoma development by oncolytic myxoma virus in a murine xenograft model of post-transplant lymphoproliferative disease.
Biochemical and biophysical research communications.
462(4):283-7
[DOI] 10.1016/j.bbrc.2015.03.146.
[PMID] 25843801.
2015
Two novel RUNX1 mutations in a patient with congenital thrombocytopenia that evolved into a high grade myelodysplastic syndrome.
Leukemia research reports.
4(1):24-7
[DOI] 10.1016/j.lrr.2015.03.002.
[PMID] 25893166.
2015
Vitamin D effect on umbilical cord blood characteristics: a comparison between African Americans and Caucasians.
Transfusion.
55(7):1766-71
[DOI] 10.1111/trf.13124.
[PMID] 25903156.
2014
A Novel Chimeric Antigen Receptor Against Prostate Stem Cell Antigen Mediates Tumor Destruction in a Humanized Mouse Model of Pancreatic Cancer
Human Gene Therapy.
25(12)
2014
Angiotensin II Regulates Hematopoietic Stem Cell Proliferation, Differentiation and Engraftment Efficacy
Experimental Hematology.
42(8, 1)
2014
Detailed analysis of bone marrow from patients with ischemic heart disease and left ventricular dysfunction: BM CD34, CD11b, and clonogenic capacity as biomarkers for clinical outcomes.
Circulation research.
115(10):867-74
[DOI] 10.1161/CIRCRESAHA.115.304353.
[PMID] 25136078.
2014
Fishing for myelodysplastic syndromes finds uncaptured cases by state cancer registries: Need for more resources.
Cancer.
120(11):1614-6
[DOI] 10.1002/cncr.28638.
[PMID] 24643687.
2014
Functional integration of acute myeloid leukemia into the vascular niche.
Leukemia.
28(10):1978-1987
[DOI] 10.1038/leu.2014.109.
[PMID] 24637335.
2014
High rate of uncaptured myelodysplastic syndrome cases and an improved method of case ascertainment.
Leukemia research.
38(1):71-5
[DOI] 10.1016/j.leukres.2013.10.023.
[PMID] 24280283.
2014
Mapping hematopoiesis in a fully regenerative vertebrate: the axolotl.
Blood.
124(8):1232-41
[DOI] 10.1182/blood-2013-09-526970.
[PMID] 24802774.
2014
Myelodysplastic Syndromes Management and Treatment: a Conceptual Framework
Haematologica.
99(1):622-623
2014
Radiation alone for solid tumors and the questionable development of therapy-related myelodysplastic syndromes.
Journal of the National Cancer Institute.
106(3)
[DOI] 10.1093/jnci/dju025.
[PMID] 24577814.
2014
Response to letter regarding article, “a detailed analysis of bone marrow from patients with ischemic heart disease and left ventricular dysfunction: BM CD34, CD11b and clonogenic capacity as biomarkers for clinical outcomes”.
Circulation research.
115(12):e36-7
[DOI] 10.1161/CIRCRESAHA.114.305422.
[PMID] 25477487.
2014
Tandem Autologous Stem Cell Transplantation for Multiple Myeloma Patients Based on Response to Their First Transplant-A Prospective Phase II Study.
Clinical Medicine Insights. Oncology.
8:101-5
[DOI] 10.4137/CMO.S16835.
[PMID] 25232286.
2013
A critical analysis of clinical outcomes reported in stem cell trials for acute myocardial infarction: some thoughts for design of future trials.
Current atherosclerosis reports.
15(8)
[DOI] 10.1007/s11883-013-0341-9.
[PMID] 23793731.
2013
Overcoming chronic myeloid leukemia stem cell resistance to imatinib by also targeting JAK2.
Journal of the National Cancer Institute.
105(6):378-9
[DOI] 10.1093/jnci/djt029.
[PMID] 23446756.
2013
PARP1 is required for chromosomal translocations.
Blood.
121(21):4359-65
[DOI] 10.1182/blood-2012-10-460527.
[PMID] 23568489.
2013
The Nhlbi Time Trial: One-Year Results
Circulation.
128(24)
2013
Variable and Decreased Clonogenic Activity of Autologous Bone Marrow in Cell Therapy Patients With Ischemic Heart Disease, and Cd34 as a Biomarker for Clinical Outcomes: Results From the Cardiovascular Cell Therapy Research Network (Cctrn)
Circulation.
128(22, S)
2012
A Phase I Study of the Vascular Disrupting Combretastatin, Oxi4503, in Patients With Relapsed and Refractory Acute Myeloid Leukemia (Aml) and Myelodysplastic Syndromes (Mds)
Blood.
120
2012
Acute myeloid leukemia targeting by myxoma virus in vivo depends on cell binding but not permissiveness to infection in vitro.
Leukemia research.
36(5):619-24
[DOI] 10.1016/j.leukres.2012.01.020.
[PMID] 22341701.
2012
Angiogenesis in acute myeloid leukemia and opportunities for novel therapies.
Journal of oncology.
2012
[DOI] 10.1155/2012/128608.
[PMID] 21904549.
2012
Characteristics of thawed autologous umbilical cord blood.
Transfusion.
52(10):2234-42
[DOI] 10.1111/j.1537-2995.2011.03556.x.
[PMID] 22321210.
2012
Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial.
JAMA.
308(22):2380-9
[PMID] 23129008.
2012
Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial.
JAMA.
307(16):1717-26
[DOI] 10.1001/jama.2012.418.
[PMID] 22447880.
2012
Extended Dosing of Oral Azacitidine (Cc-486) for 14 and 21 Days Provides More Effective Methylation Reversal Than a 7-Day Schedule
Blood.
120
2012
Factors affecting the turnaround time for manufacturing, testing, and release of cellular therapy products prepared at multiple sites in support of multicenter cardiovascular regenerative medicine protocols: a Cardiovascular Cell Therapy Research Network (CCTRN) study.
Transfusion.
52(10):2225-33
[DOI] 10.1111/j.1537-2995.2011.03543.x.
[PMID] 22320233.
2012
Oncolytic virotherapy for hematological malignancies.
Advances in virology.
2012
[DOI] 10.1155/2012/186512.
[PMID] 22312362.
2012
Peripheral Blood Cd34(+) Specific Donor Chimerism Analysis as An Early Indicator of Disease Relapse After Allogeneic Hematopoietic Stem Cell Transplant in Patients With Myelodysplastic Syndromes and Acute Myelogenous Leukemia.
Blood.
120
2012
Response Post-First Autologous Stem Cell Transplantation for Multiple Myeloma May Identify Patients Who Will Benefit From Tandem Transplants: a Single Center Prospective Phase II Study- An Update
Blood.
120
2012
Safety and Efficacy of Oral Azacitidine (Cc-486) Administered in Extended Treatment Schedules To Patients With Lower-Risk Myelodysplastic Syndromes
Blood.
120
2012
Selective purging of human multiple myeloma cells from autologous stem cell transplantation grafts using oncolytic myxoma virus.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
18(10):1540-51
[DOI] 10.1016/j.bbmt.2012.04.004.
[PMID] 22516053.
2012
Single Versus Tandem Autologous Stem Cell Transplantation (Asct) for Multiple Myeloma Patients and Role of Second Salvage Transplant: a Single Center Prospective Phase Ii Study
Biology of Blood and Marrow Transplantation.
18(2)
[DOI] 10.1016/j.bbmt.2011.12.244.
2012
The Effect of Timing of Stem Cell Delivery Following Acute Myocardial Infarction: the Nhlbi and Cctrn Time Trial
Circulation.
126:2783-2784
2012
The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosis.
The American journal of pathology.
181(3):858-65
[DOI] 10.1016/j.ajpath.2012.05.033.
[PMID] 22796437.
2012
Underreporting of myeloid malignancies by United States cancer registries.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
21(3):474-81
[DOI] 10.1158/1055-9965.EPI-11-1087.
[PMID] 22237987.
2012
Vascular Disrupting Combretastatins Impair Bone Marrow Endothelial Cells By Depolymerizing the Microtubule Cytoskeleton
Blood.
120
2012
Virotherapy using myxoma virus prevents lethal graft-versus-host disease following xeno-transplantation with primary human hematopoietic stem cells.
PloS one.
7(8)
[DOI] 10.1371/journal.pone.0043298.
[PMID] 22905251.
2011
Developing mechanistic insights into cardiovascular cell therapy: Cardiovascular Cell Therapy Research Network Biorepository Core Laboratory rationale.
American heart journal.
162(6):973-80
[DOI] 10.1016/j.ahj.2011.05.024.
[PMID] 22137069.
2011
Diagnostic testing, treatment, cost of care, and survival among registered and non-registered patients with myelodysplastic syndromes.
Leukemia research.
35(11):1453-6
[DOI] 10.1016/j.leukres.2011.07.028.
[PMID] 21851978.
2011
Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial.
JAMA.
306(19):2110-9
[DOI] 10.1001/jama.2011.1670.
[PMID] 22084195.
2011
Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries.
Blood.
117(26):7121-5
[DOI] 10.1182/blood-2011-02-337964.
[PMID] 21531980.
2011
Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
29(18):2521-7
[DOI] 10.1200/JCO.2010.34.4226.
[PMID] 21576646.
2011
Results From Latetime: a Randomized, Placebo Controlled Trial of Intracoronary Stem Cell Delivery Two To Three Weeks Following Acute Myocardial Infarction
Circulation.
124
2011
The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrow.
Neoplasia (New York, N.Y.).
13(11):1058-68
[PMID] 22131881.
2011
The stilbenoid tyrosine kinase inhibitor, G6, suppresses Jak2-V617F-mediated human pathological cell growth in vitro and in vivo.
The Journal of biological chemistry.
286(6):4280-91
[DOI] 10.1074/jbc.M110.200774.
[PMID] 21127060.
2010
Acute Myeloid Leukemia Cells Depend On Vegf, Pdgfr and Scf Receptor Signaling: Leukemia Regression With Pazopanib
Blood.
116
2010
Evaluation of Oral Azacitidine Using Extended Treatment Schedules: a Phase I Study
Blood.
116:265-266
2010
High Rate of Uncaptured Myelodysplastic Syndrome Cases At the State Cancer Registry Level
Blood.
116
2010
Hypomethylating agent induction therapy followed by hematopoietic cell transplantation is feasible in patients with myelodysplastic syndromes.
Clinical advances in hematology & oncology : H&O.
8(1):40-6
[PMID] 20351682.
2010
Intramyocardial injection of autologous bone marrow mononuclear cells for patients with chronic ischemic heart disease and left ventricular dysfunction (First Mononuclear Cells injected in the US [FOCUS]): Rationale and design.
American heart journal.
160(2):215-23
[DOI] 10.1016/j.ahj.2010.03.029.
[PMID] 20691824.
2010
LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction.
Texas Heart Institute journal.
37(4):412-20
[PMID] 20844613.
2010
Leukemia regression by vascular disruption and antiangiogenic therapy.
Blood.
116(9):1539-47
[DOI] 10.1182/blood-2009-06-230474.
[PMID] 20472832.
2010
Multicenter cell processing for cardiovascular regenerative medicine applications: the Cardiovascular Cell Therapy Research Network (CCTRN) experience.
Cytotherapy.
12(5):684-91
[DOI] 10.3109/14653249.2010.487900.
[PMID] 20524773.
2010
Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virus.
Cytokine & growth factor reviews.
21(2-3):169-75
[DOI] 10.1016/j.cytogfr.2010.02.010.
[PMID] 20211576.
2009
A Comparative Pharmacokinetic/Pharmacodynamic (Pk/Pd) Evaluation of Azacitidine Following Subcutaneous (Sc) and Oral Administration in Subjects With Myelodysplastic Syndromes (Mds) Or Acute Myelogenous Leukemia (Aml), Results From a Phase 1 Study
Blood.
114
2009
A Phase 1, Open-Label, Dose-Escalation Study To Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Patients With Myelodysplastic Syndromes (Mds) Or Acute Myelogenous Leukemia (Aml)
Blood.
114
2009
Aldehyde dehydrogenase activity as a functional marker for lung cancer.
Chemico-biological interactions.
178(1-3):48-55
[DOI] 10.1016/j.cbi.2008.09.029.
[PMID] 18952074.
2009
Aml Regression By Vascular Disruption With Oxi4503 and Anti-Angiogenesis With Bevacizumab.
Blood.
114
2009
Bone marrow stem and progenitor cell contribution to neovasculogenesis is dependent on model system with SDF-1 as a permissive trigger.
Blood.
114(19):4310-9
[DOI] 10.1182/blood-2009-03-211342.
[PMID] 19717647.
2009
Impact of An Annual Hematology/Oncology Fellow Wet Laboratory Program On Fund of Biomedical Knowledge
Blood.
114
2009
Impact of Azacytidine Induction Chemotherapies On Post-Transplant Outcomes in Patients With Myelodysplastic Syndromes
Journal of Clinical Oncology.
27
2009
Myxoma virus targets primary human leukemic stem and progenitor cells while sparing normal hematopoietic stem and progenitor cells.
Leukemia.
23(12):2313-7
[DOI] 10.1038/leu.2009.219.
[PMID] 19865109.
2009
Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction.
American heart journal.
158(3):356-63
[DOI] 10.1016/j.ahj.2009.06.009.
[PMID] 19699857.
2009
Time From Onset of Acute Anterior Myocardial Infarction Negatively Influences Bone Marrow Cell Function: Preliminary Data From the Nhlbi Cctrn Ancillary Studies
Circulation.
120
2008
Marrow cell therapies for cardiovascular diseases.
Experimental hematology.
36(6):687-94
[DOI] 10.1016/j.exphem.2008.01.012.
[PMID] 18375038.
2008
Non-Myeloablative Allogeneic Stem Cell Transplantation To Treat High Risk Heavily Pretreated Multiple
Biology of Blood and Marrow Transplantation.
14(2):69-70
[DOI] 10.1016/j.bbmt.2007.12.198.
2007
Bone marrow contributes to epithelial cancers in mice and humans as developmental mimicry.
Stem cells (Dayton, Ohio).
25(8):1881-7
[PMID] 17478582.
2007
Optimization of a myeloid cell transfusion strategy for infected neutropenic hosts.
Journal of leukocyte biology.
81(3):632-41
[PMID] 17158608.
2007
The hunt for cancer-initiating cells: a history stemming from leukemia.
Leukemia.
21(8):1619-27
[PMID] 17541397.
2006
Donor-derived type II pneumocytes are rare in the lungs of allogeneic hematopoietic cell transplant recipients.
Annals of clinical and laboratory science.
36(1):47-52
[PMID] 16501236.
2006
Stem cell research.
Paediatric respiratory reviews.
7(2):135-40
[PMID] 16765300.
2006
The thrombopoietin receptor, c-Mpl, is a selective surface marker for human hematopoietic stem cells.
Journal of translational medicine.
4
[PMID] 16480521.
2005
Bone marrow-derived stem-cell repopulation contributes minimally to the Type II pneumocyte pool in transplanted human lungs.
Transplantation.
80(2):206-12
[PMID] 16041265.
2005
Developmental differences in megakaryocyte maturation are determined by the microenvironment.
Stem cells (Dayton, Ohio).
23(9):1400-8
[PMID] 16210411.
2005
Distinct hematopoietic progenitor compartments are delineated by the expression of aldehyde dehydrogenase and CD34.
Blood.
106(1):95-102
[PMID] 15790790.
2004
Adult human hematopoietic cells provide functional hemangioblast activity.
Blood.
103(1):133-5
[PMID] 12969964.
2004
Bone marrow transdifferentiation in brain after transplantation: a retrospective study.
Lancet (London, England).
363(9419):1432-7
[PMID] 15121406.
2004
The hemangioblast: cradle to clinic.
Experimental hematology.
32(10):885-90
[PMID] 15504543.
2003
An overview of stem cell research and regulatory issues.
Mayo Clinic proceedings.
78(8):993-1003
[PMID] 12911047.
2003
Busulfan, cyclophosphamide, and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma.
American journal of hematology.
73(3):169-75
[PMID] 12827653.
2003
Typhlitis with concurrent appendicitis in a patient with chronic lymphocytic leukemia.
Clinical advances in hematology & oncology : H&O.
1(5):284-6; discussion 286
[PMID] 16224422.
Grants
Jan 2025
ACTIVE
Foundation for Sickle Cell Disease Research (FSCDR) For the SCD
Role: Principal Investigator
Funding: FOU FOR SICKLE CELL DISEASE RES
Jan 2025
ACTIVE
OneFlorida+ Clinical Research Network Phase 4
Role: Co-Investigator
Funding: PATIENT-CENTERED OUTCOMES RES INST
Jul 2024
ACTIVE
Health Policy Training in Tobacco Prevention and Control
Role: Principal Investigator
Funding: FL DEPT OF HLTH
Dec 2023
– Jun 2024
Health Policy Training in Tobacco Prevention and Control
Role: Principal Investigator
Funding: FL DEPT OF HLTH
Dec 2023
ACTIVE
Chief Medical Officer for Florida Medicaid, Agency for Health Care Administration
Role: Principal Investigator
Funding: AGCY FOR HLTH CARE ADMN
Sep 2023
ACTIVE
Blood Disorder Program: Prevention, Surveillance, and Research
Role: Principal Investigator
Funding: UNIV OF MIAMI
via CTRS FOR DISEASE CONTROL AND PREVENTION
Sep 2022
– Jun 2023
Health Policy Training in Tobacco Prevention and Control
Role: Principal Investigator
Funding: FL DEPT OF HLTH
May 2022
ACTIVE
Comparative Effectiveness of Mobile Health Smoking Cessation Approaches among Underserved Patients in Primary Care
Role: Co-Investigator
Funding: PATIENT-CENTERED OUTCOMES RES INST
Nov 2021
– Jun 2022
FLDOH PO – 2021-2022 – Educating Community Leaders about Tobacco Regulation
Role: Principal Investigator
Funding: FL DEPT OF HLTH
Mar 2021
– Dec 2023
AHCA contract for CMO
Role: Principal Investigator
Funding: AGCY FOR HLTH CARE ADMN
Feb 2021
– Jun 2021
Health Policy Training in Tobacco Prevention and Cessation
Role: Principal Investigator
Funding: FL DEPT OF HLTH
Jul 2020
– Jun 2023
Targeting MDS with a BiTE
Role: Principal Investigator
Funding: UF FOUNDATION
via OXNARD FOUNDATION
Mar 2020
– Sep 2023
PHASE 1/1B OPEN-LABEL, DOSE-ESCALATION STUDY OF APVO436 IN PATIENTS WITH RELAPSED OR REFRACTORY AML OR HIGH-GRADE MDS
Role: Principal Investigator
Funding: FORTREA
via APTEVO RESEARCH AND DEVELOPMENT
Apr 2019
– Dec 2024
LLS funding for Improving risk assessment of AML with a precision genomic strategy to assess mutation clearance
Role: Principal Investigator
Funding: LEUKEMIA & LYMPHOMA SOC
Jun 2018
– Jun 2019
Pilot Study of Lenalidomide Sensitivity and Resistance Mechanisms in Non-Del(5q) Myelodysplastic Syndromes
Role: Principal Investigator
Funding: CELGENE CORP
Nov 2017
– Oct 2022
The Harry T. Mangurian, Jr. Foundation – Support for the Study of Therapy Resistant Leukemia
Role: Co-Project Director/Principal Investigator
Funding: UF FOUNDATION
via HARRY T MANGURIAN JR FOU
Jun 2017
– May 2021
DRPD-R0F2017: An Integrated Multi-'omics' Analysis of Myelodysplastic Syndromes
Role: Co-Investigator
Funding: UF DSR OPPORTUNITY FUND
Jun 2017
– May 2018
Laboratory Studies of Acute Lymphoblastic Leukemia
Role: Principal Investigator
Funding: CELL WORKS GROUP, INC.
Apr 2017
– Jun 2021
OoR CTSI Institutional Matching Support
Role: Project Manager
Funding: UF DIV OF SPONSORED RES MATCHING FUNDS
Oct 2016
– Oct 2021
A Phase 3, Multicenter, Open-Label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects with Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation
Role: Principal Investigator
Funding: CELGENE CORP
Aug 2016
– Aug 2021
A Phase III, International, Randomized, Controlled Study of Rigosertib versus Physicians Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent
Role: Principal Investigator
Funding: ONCONOVA THERAPEUTICS
Jun 2016
– Jun 2021
214 Fund A Randomized, Multicenter, Open-Label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination with Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (>= 65 Years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplant (HSCT)
Role: Principal Investigator
Funding: CELGENE CORP
May 2016
– Dec 2017
Beat AML Project: Personalized Medicine for AML Based on Functional Genomics
Role: Principal Investigator
Funding: OREGON HLTH & SCIENCES UNIV
via LEUKEMIA & LYMPHOMA SOC
Jan 2016
– Jun 2022
Miscellaneous Donors
Role: Principal Investigator
Funding: MISCELLANEOUS DONORS
Jan 2016
– Jan 2021
A Phase 2, Open-Label, Single-Arm Rollover Study to Evaluate Long-Term Safety in Subjects Who Participated In Other Celgene Sponsored CC-486 (Oral Azacitadine) Clinical Trials and Hematologic Disorders
Role: Principal Investigator
Funding: CELGENE CORP
Nov 2015
– Mar 2022
A Phase 1b Dose Escalation Study of Oxi4503 as a Single Agent and in Combination with Cytarabine with Subsequent Combination Phase 2 Cohorts for Subjects with Relapsed/Refractory Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS)
Role: Principal Investigator
Funding: MATEON THERAPEUTICS
Oct 2015
– Dec 2017
Exploratory Analyses for OX1222
Role: Principal Investigator
Funding: MATEON THERAPEUTICS
Sep 2015
– Oct 2019
Personalized Genomic Mutation Informed Treatment of Patients with Myelodysplastic Syndromes (MDS)
Role: Principal Investigator
Funding: GATEWAY FOR CANCER RESEARCH
Feb 2015
– Jan 2020
UF Health Cancer Center Collaborative Cancer Related Seed Grant funded through the Florida Consortium of National Cancer Institute Centers Program
Role: Project Manager
Funding: UF HEALTH SHANDS HOSPITAL
Nov 2014
– Oct 2015
Mapping Cancer in Alachua County
Role: Principal Investigator
Funding: UF MEDICAL GUILD
Oct 2014
– Nov 2022
CONNECT MDS/AML DISEASE REGISTRY
Role: Principal Investigator
Funding: UNITED BIOSOURCE
via CELGENE CORP
Oct 2014
– Mar 2017
Connect MDS/AML Disease Registry
Role: Principal Investigator
Funding: UNITED BIOSOURCE
via CELGENE CORP
Jan 2014
– Jul 2018
Anemia and the Chronic Hyperadrenergic State following Major Trauma
Role: Project Manager
Funding: NATL INST OF HLTH NIGMS
Jan 2014
– Dec 2016
Role of the Microenvironment in Acute Myeloid Leukemia
Role: Principal Investigator
Funding: LEUKEMIA & LYMPHOMA SOC
Dec 2013
– Nov 2016
Targeting Histone Methylation for Triple-Negative Breast Cancer Therapy
Role: Project Manager
Funding: FL DEPT OF HLTH BANKHEAD-COLEY CANCER RE
Sep 2013
– Dec 2020
Chagnon Professorship – research in field of stem cell biology and bone marrow transplantation
Role: Project Manager
Funding: UF FOUNDATION
Dec 2012
– Dec 2018
Adipose-Derived Regenerative Cells in the Treatment of Patients with Chronic Ischemic Heart Disease Not Amenable to Surgical or Interventional Revascularization
Role: Project Manager
Funding: CYTORI THERAPEUTICS
Jul 2012
– Jun 2017
Vascular Targeting Therapy in AML and MDS
Role: Principal Investigator
Funding: LEUKEMIA & LYMPHOMA SOC
Mar 2012
– Mar 2016
A prospective, randomized, double-blinded, active-control and unblindedstandard of care (SOC) controlled study to determine the efficacy and safety oftargeted intramyocardial delivery of autologous CD34+ cells (Auto-CD34+cells) for increasing exerc
Role: Project Manager
Funding: PPD DEVELOPMENT
via BAXTER HEALTHCARE CORP
Mar 2012
– Aug 2020
UFRCC for Cardiovascular Cell Therapy Research Network
Role: Co-Investigator
Funding: NATL INST OF HLTH NHLBI
Feb 2012
– May 2017
A Prospective Randomized Double Blinded Placebo Controlled Phase II Trial of Intra-coronary Infusion of AMR-001, a Bone Marrow Derived Autologous CD34+ Selected Cell Product, in Patients with Acute Myocardial Infarction
Role: Project Manager
Funding: AMORCYTE
Feb 2012
– Jun 2022
Davis Cancer Endowment – #F014842
Role: Project Manager
Funding: UF FOUNDATION
Feb 2012
– Jan 2019
Novel technology for targeting and eliminating cancer cells that contaminate bone marrow transplants
Role: Principal Investigator
Funding: UF FOUNDATION
Nov 2009
– Nov 2018
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE JAK INHIBITOR INCB018424 TABLETS ADMINISTERED ORALLY…….
Role: Principal Investigator
Funding: PPD DEVELOPMENT
via INCYTE CORPORATION
Nov 2009
– Dec 2016
A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia Myelofibrosis (
Role: Principal Investigator
Funding: PPD DEVELOPMENT
via INCYTE CORPORATION
Jun 2008
– Nov 2019
A Phase 1, Open-Label, dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
Role: Principal Investigator
Funding: CELGENE CORP
Jul 2007
– Aug 2016
Clinical and Translational Science Institute
Role: Project Manager
Funding: UF RESEARCH FOU
Jul 2006
– Dec 2020
21st Century Research & Economic Development Investment Program (REDIP)
Role: Project Manager
Funding: STATE UNIV SYS OF FL BOARD OF GOVERNORS
Education
Fellowship – Blood & Marrow Transplant and Stem Cell Biology
2003
·
Duke University
Fellowship – Medical Oncology
2003
·
University of Florida
Residency – Internal Medicine
2000
·
University of Florida
Medical Doctorate (M.D.)
1997
·
University of Florida
Bachelor of Science (B.S.) in Biomedical Sciences
1994
·
University of Florida
Contact Details
Phones:
- Business:
- (352) 273-7832
Emails:
- Business:
- christopher.cogle@medicine.ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100278
1600 SW ARCHER RD
GAINESVILLE FL 32610 - Business Street:
-
1200 NEWELL DR # 220
PUGH HALL
GAINESVILLE FL 32610